Patients Harboring ALK Rearrangement Adenocarcinoma after Acquired Resistance to Crizotinib and Transformation to SCLC: A Case Report

被引：0
|
作者：
Wang, W. [1 ]
Xu, C. [2 ]
Zhu, Y. [3 ]
Liao, X. [4 ]
Zhuang, W. [5 ]
Du, K. [3 ]
Chen, R. [6 ]
Chen, Y. [2 ]
Chen, G. [2 ]
Fang, M. [1 ]
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[2] Fujian Prov Canc Hosp, Pathol, Fuzhou, Fujian, Peoples R China
[3] Zhejiang Rongjun Hosp, Chest Dis Diag & Treatment Ctr, Jiaxing, Peoples R China
[4] Zhejiang Rongjun Hosp, Tumor Mol Lab, Jiaxing, Peoples R China
[5] Fujian Prov Canc Hosp, Med Oncol, Fuzhou, Fujian, Peoples R China
[6] Geneplus Beijing, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
crizotinib; Resistance; small-cell lung cancer;
D O I：
10.1016/j.jtho.2017.09.1548
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02-018
引用
收藏
页码：S2244 / S2244
页数：1
相关论文
共 50 条
  • [21] AlectinibTransformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib : case report
    Reactions Weekly, 2016, 1607 (1) : 35 - 35
  • [22] Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review
    Xu, Lingling
    Chen, Maoxi
    Ye, Wei
    Zhao, Jieting
    Yao, Yuanyuan
    Xu, Ning
    LUNG CANCER, 2023, 186
  • [23] Alectinib/ceritinib/lorlatinibDevelopment of resistance in SCLC and SCLC transformation: case report
    Reactions Weekly, 2017, 1648 (1) : 21 - 21
  • [24] THE CASE REPORT OF LUNG ADENOCARCINOMA THYROID METASTASIS OF ALK REARRANGEMENT
    Tian, Tian
    Hong, Fu
    Zhang, Zhihong
    Qian, Liting
    ACTA MEDICA MEDITERRANEA, 2020, 36 (03): : 1307 - 1310
  • [25] Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib
    Takegawa, N.
    Hayashi, H.
    Iizuka, N.
    Takahama, T.
    Ueda, H.
    Tanaka, K.
    Takeda, M.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2016, 27 (05) : 953 - 955
  • [26] Bevacizumab/carboplatin/crizotinib/gemcitabine/paclitaxelAcquired resistance and transformation of adenocarcinoma to sarcomatoid carcinoma: case report
    Reactions Weekly, 2015, 1554 (1) : 44 - 44
  • [27] Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
    Zhang, Xiangming
    Ni, Kai
    Chen, Huijun
    ONCOTARGETS AND THERAPY, 2023, 16 : 87 - 90
  • [28] AntineoplasticsEGFR and KRAS mutations with acquired resistance to crizotinib: case report
    Reactions Weekly, 2014, 1515 (1) : 31 - 31
  • [29] A CASE OF LUNG ADENOCARCINOMA RESISTANT TO CRIZOTINIB HARBORING KRAS MUTATION AND EML4-ALK FUSION GENE
    Anai, Satoshi
    Suzuki, Kunihiro
    Sueishi, Katsuo
    Harada, Taishi
    Toyokawa, Gouji
    Seto, Takashi
    Takenoyama, Mitsuhiro
    Takayama, Koichi
    Ichinose, Yukito
    Nakanishi, Yoichi
    ANNALS OF ONCOLOGY, 2014, 25
  • [30] CrizotinibDevelopment of crizotinib-resistance in lung adenocarcinoma: case report
    Reactions Weekly, 2017, 1635 (1) : 96 - 96
12345